Prospects for the therapeutic development of umbilical cord blood-derived mesenchymal stem cells

World J Stem Cells. 2020 Dec 26;12(12):1511-1528. doi: 10.4252/wjsc.v12.i12.1511.

Abstract

Umbilical cord blood (UCB) is a primitive and abundant source of mesenchymal stem cells (MSCs). UCB-derived MSCs have a broad and efficient therapeutic capacity to treat various diseases and disorders. Despite the high latent self-renewal and differentiation capacity of these cells, the safety, efficacy, and yield of MSCs expanded for ex vivo clinical applications remains a concern. However, immunomodulatory effects have emerged in various disease models, exhibiting specific mechanisms of action, such as cell migration and homing, angiogenesis, anti-apoptosis, proliferation, anti-cancer, anti-fibrosis, anti-inflammation and tissue regeneration. Herein, we review the current literature pertaining to the UCB-derived MSC application as potential treatment strategies, and discuss the concerns regarding the safety and mass production issues in future applications.

Keywords: Immunomodulation; Mesenchymal stem cell; Regenerative medicine; Stem cell therapy; Therapeutic cell manufacturing processing; Umbilical cord blood.

Publication types

  • Review